The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma by unknown
RESEARCH ARTICLE Open Access
The prognostic value of serum CA 19-9
for patients with advanced lung
adenocarcinoma
Yuki Sato1, Daichi Fujimoto1*, Keiichiro Uehara2, Ryoko Shimizu1, Jiro Ito1, Mariko Kogo1, Shunsuke Teraoka1,
Ryoji Kato1, Kazuma Nagata1, Atsushi Nakagawa1, Kojiro Otsuka1, Hiroshi Hamakawa3, Yutaka Takahashi3,
Yukihiro Imai2 and Keisuke Tomii1
Abstract
Background: This study aimed to assess the prognostic accuracy of serum CA 19-9 in patients with advanced lung
adenocarcinoma.
Methods: We retrospectively reviewed data of 246 patients who were diagnosed at our institute with advanced
(stage IIIB or IV) lung adenocarcinoma between March 2006 and December 2012. We excluded patients who
received no chemotherapy, or for whom we had no data on pre-treatment tumor markers. We also evaluated
116 consecutive resected specimens from patients with clinical stage I lung adenocarcinoma pathologically.
Results: The 76 (31 %) patients who were CA 19-9+ had shorter overall survival (OS) than CA 19-9− group
(12.5 vs 26.2 months, P = 0.005). Cox’s multivariate regression analysis identified Eastern Cooperative Oncology Group
Performance Status 0 or 1 (P < 0.001), mutated epidermal growth factor receptor (EGFR) status (P < 0.001), stage IIIB
(P < 0.001), CYFRA 21-1− (P < 0.001), CA 19-9− (P = 0.005) and use of platinum doublet therapy (P = 0.034) as independent
predictors of longer OS. We stratified patients by CA 19-9 and CYFRA 21-1 as double positive (CA 19-9+/CYFRA 21-1+,
n= 59), single positive (either CA19-9+ or CYFRA 21-1+, n = 113), or double negative (CA 19-9−/CYFRA 21-1−, n = 74). Their
respective OS were 10.0, 23.3 and 31.8 months (P < 0.001). Pathological analysis also correlated CA 19-9 expression with
malignant features such as vessel invasion, pleural invasion, cancer invasive factors and mucin production.
Conclusions: CA 19-9 and CYFRA 21-1 are independent prognostic markers in patients with advanced lung
adenocarcinoma. Combined use of CA 19-9 and CYFRA 21-1 provides further prognostic information in patients with
advanced lung adenocarcinoma.
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Background
Lung cancer is the leading cause of cancer death worldwide.
Unfortunately, most lung cancers are already unresectable
and metastatic at initial diagnosis [1, 2]. Overall survival
(OS) of patients with advanced lung adenocarcinoma
(ALAD) is still very poor, despite progress in treatment and
chemotherapy. ALAD prognosis can be assessed through
various factors, such as pathologic characteristics, imaging
features, and oncogenes, but identification of more accurate
prognostic markers is imperative.
Measurement of tumor markers is a non-invasive
means to predict prognosis, and is therefore used in
daily clinical practice [3]. Earlier investigations of the re-
lationships between prognosis and serum cytokeratin
19 fragments (CYFRA 21-1), carcinoembryonic antigen
(CEA) or neuron-specific enolase (NSE) in ALAD pa-
tients found only CYFRA 21-1 to be an independent
prognostic marker among them [4–6]. Therefore, identi-
fication of another independent prognostic tumor
marker would have great value in managing these
patients.
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Carbohydrate antigen 19-9 (CA 19-9) is a tumor-
associated antigen originally isolated from a human
colorectal cancer cell line in 1979 by Koprowski [7].
Since development of radioimmunometric assays, CA
19-9 has been used to monitor various cancer types, and
is used as a prognostic marker in pancreatic, colon, and
stomach adenocarcinoma [8–15].
Although patients with ALAD who show extremely
high serum levels of CA 19-9 are reportedly have poor
prognoses, the relationship between serum CA 19-9 and
prognosis in lung adenocarcinoma has not been studied
yet [16, 17]. We hypothesized that CA 19-9 is a prognos-
tic marker for ALAD patients.
The purpose of this study was to investigate the clin-
ical utility of CA 19-9 as a prognostic marker in ALAD
patients, and to improve its prognostic accuracy.
Methods
Study subjects
We retrospectively analyzed 433 patients diagnosed ad-
vanced (stage IIIB or IV) lung adenocarcinoma at Kobe
City Medical Center General Hospital between March
2006 and December 2012. We excluded patients who re-
ceived no chemotherapy (n = 71), or for whom no data
on tumor markers (CEA, CYFRA 21-1 and CA 19-9) be-
fore receiving chemotherapy was available (n = 116). Pa-
tients who reported never having smoked were defined
as never-smokers, those who had smoked within 1 year
of the diagnosis were categorized as current smokers,
and the rest were considered to be former smokers. All
patients were classified by clinical stage according to the
7th edition TNM (tumor, node, metastasis) classification
[18]. OS was measured from the diagnosis of lung cancer
until death from any cause or the end of the follow-up.
We isolated tumor DNA from various specimens and ana-
lyzed epidermal growth factor receptor gene (EGFR) mu-
tation status at exons 18–21, using the peptide nucleic
acid-locked nucleic acid PCR clamp methods, as described
previously [19]. We retrospectively analyzed the presence
of intestinal pneumonia, non-tuberculous mycobacteriosis
(NTM) infection, bronchiectasis, and diffuse panbronchio-
litis by reviewing patients’ charts and radiological records.
Determination of tumor markers concentration
Serum samples were obtained to determine tumor markers
CEA, CYFRA 21-1 and CA 19-9 as a part of routine evalu-
ations within 28 days before starting chemotherapy. The
concentration of each tumor makers was measured using
LumiPulse Presto kit (Fujirebio Inc., Tokyo, Japan). It uti-
lizes the chemiluminescent enzyme immunoassay (CLEIA)
principle and is a fully automated assay [20]. The CLEIA
method uses 1.6 ng/mL as the upper limit of normal
(ULN) serum CYFRA 21-1 level in healthy individuals [21].
For this study, we set the cutoff value for CYFRA 21-1 at
2.2 ng/mL, which was used in a previous study that showed
the prognostic impact of CYFRA 21-1 in patients with
ALAD, and is the mean value for healthy subjects +3 SD
(standard deviation) [4]. The cutoff values for serum CEA
and CA 19-9 were set at 5.0 ng/mL and 37.0 U/mL, which
are their respective ULNs [22, 23]. This testing was per-
formed at the Department of Laboratory Medicine at our
hospital.
Pathological analysis
Additionally, we retrospectively analyzed post-operative
specimens from patients with clinical stage I lung adenocar-
cinoma who underwent surgery at our hospital between
January 2008 and May 2010. We evaluated the presence of
vessel invasion, pleural invasion, lymph node metastasis
and postoperative pathological stage. The presence of
mucin was also assessed using diastase-resistant periodic
acid Schiff (D-PAS) staining in all samples with 5 % incre-
ments (Fig. 1a, b) [24, 25]. We tested CA 19-9 expression,
immunohistochemically (IHC), using the 116-NS-19-9
antibody (Covance Inc., Princeton, USA). We applied
the expression score, which was described previously
[26–28]. Percentages of CA 19-9+ tumor cells (propor-
tion score) was scored as 0: none (0 %); 1: 1–10 %; 2:
11–30 %; 3: 31–50 %; 4: 51–70 %; and 5: 71–100 % of each
tumor sample. The intensity of staining (intensity score)
was scored as 0: no staining; 1: weak staining; 2: moderate
staining; and 3: strong staining in >10 % of cancer cells
(Fig. 1c–f). The proportion score and intensity score were
added to yield a total expression score of 0–8; samples that
scored ≥ 3 were defined as CA 19-9+. We defined cases
with at least one of the pathologic invasive factors—vessel
invasion, pleural invasion, or lymph node metastasis—as
positive for cancer invasive factors [29]. All pathological
analyses were evaluated by two experienced pathologists
who were unaware of the patients’ conditions.
Statistical analysis
Continuous variables were analyzed using Student’s t-test.
Dichotomous variables were analyzed using Fisher’s exact
test. Correlations between CA 19-9 levels and CYFRA 21-1
levels were assessed using Spearman’s rank-based correl-
ation test. The Kaplan −Meier method was used to esti-
mate survival outcomes; groups were compared using the
log-rank test. Cox’s proportional hazard models were fitted
to determine associations between patient characteristics
and survival outcomes. A multivariate Cox proportional
hazard model was developed on all clinically important fac-
tors (age, sex, smoking status, ECOG PS, EGFR status,
stage, positivity of serum CEA, CYFRA 21-1 and CA 19-9,
and platinum doublet therapy administration). The results
are expressed as hazard ratios (HRs) with 95 % confidence
intervals (CI). All tests were two-tailed. A value of P < 0.05
was considered to indicate significance. We conducted
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statistical analyses on JMP software (11th version; SAS Insti-
tute, Cary, NC, USA).
Results
Patient characteristics
We included 246 patients with ALAD in the study
(Fig. 2). Patient characteristics and comparison of clinical
profiles of CA 19-9+ and CA 19-9− patients are shown in
Table 1. Their median age was 67 years (interquartile range,
61–75 years); 184 (75 %) patients had Eastern Cooperative
Oncology Group Performance Status (ECOG PS) of 0 or 1;
and 26 (11 %) patients had stage IIIB disease. Of the 246
patients, 100 (41 %) had EGFR mutations in their speci-
mens, and 22 (9 %) had chronic lung inflammatory diseases
(16 with interstitial pneumonia, 3 with NTM infection, and
3 with bronchiectasis). We found 163 (66 %) were CEA+
(>5.0 ng/ml), 155 (63 %) were CYFRA 21-1+ (>2.2 ng/ml)
and 76 (31 %) were CA 19-9+ (>37.0 U/mL). Chemotherapy
regimens of patients who did not receive platinum doublet
therapy were tyrosine kinase inhibitors: n = 34; pemetrexed:
n = 18; TS-1: n = 6; paclitaxel: n = 5; vinorelbine: n = 4;
gemcitabine: n = 4; docetaxel: n = 3; and gemcitabine/
vinorelbine therapy: n = 2.
Comparison of clinical profiles of CA 19-9− and CA
19-9+ patients showed the CA 19-9− group included a sig-
nificantly higher percentage of patients with ECOG PS 0 or
1 status (P < 0.001), serum CYFRA 21-1− (P = 0.002), and
platinum doublet therapy administration (P = 0.007). EGFR
Fig. 2 Patient selection and exclusion criteria. Patients were stratified into 3 groups by their serum tumor markers: double positive (Double +): CA
19-9+/CYFRA 21-1+; single positive (Single +): either CA 19-9+ or CYFRA 21-1+; and double negative (Double −): CA 19-9−/CYFRA 21-1−. Median
survival time of each group is indicated in months (with ranges). ALAD: advanced lung adenocarcinoma; CYFRA 21-1: cytokeratin 19 fragments;
CA 19-9: carbohydrate antigen 19-9; + positive; −: negative; MST: median survival time
Fig. 1 a, b Stage I adenocarcinoma specimens (diastase-resistant periodic acid Schiff stain; × 400, A: negative; B: positive). c–f Immunohistochemical
staining of stage I adenocarcinoma specimens with antibodies specific for 116-NS-19-9. Representative staining patterns for c: intensity 0; d: intensity 1;
e: intensity 2; and f: intensity 3 (×400)
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status (P= 0.888) and presence of inflammatory lung disease
(P= 0.147) did not statistically differ between the two groups.
Clinical profiles of CYFRA 21-1− and CYFRA 21-1+
patients are compared in (Additional file 1: Table S1).
The CYFRA 21-1− group had a significantly higher percent-
age of patients with ECOG PS 0 or 1 status (P = 0.002),
inflammatory lung disease (P = 0.020), serum CA 19-9−
(P = 0.002), and platinum doublet therapy administration
(P = 0.046). EGFR status (P = 0.502) did not statistically
differ between the two groups.
Test of correlation between CA 19-9 levels and CYFRA
21-1 levels showed no significant relationship between
these tumor markers (r = 0.006). The scatter plot is shown
in (Additional file 2: Figure S1).
Survival analysis according to the tumor markers
The OS of patients included in this study was 21.4 months
(interquartile range, 18.9 − 25.0 months; Table 2). Overall
survival curves of CA 19-9+ and CA 19-9− patients are
shown in Fig. 3a. The OS of serum CA 19-9+ patients
Table 1 Characteristics and differences by serum CA 19-9 levels in patients with advanced-stage lung adenocarcinoma
Patient characteristics Total n (%) (n = 246) CA 19-9 positive n (%) (n = 76) CA 19-9 negative n (%) (n = 170) P
Age (years)
SD 10.4 10.7 10.2 0.160
Mean 67.1 68.5 66.5
Sex
Male 154 (63) 47 (62) 107 (63) 0.887
Female 92 (37) 29 (38) 63 (37)
Smoking status
Never 101 (41) 29 (38) 72 (42) 0.577
Current or former 145 (59) 47 (62) 98 (58)
ECOG PS
0 or 1 184 (75) 46 (61) 138 (81) <0.001
2–4 62 (25) 30 (39) 32 (19)
Stage
IIIB 26 (11) 6 (8) 20 (12) 0.501
IV 220 (89) 70 (92) 150 (88)
EGFR status
Mutated 100 (41) 30 (39) 70 (41) 0.888*
Exon 19 deletion 45 (18) 16 (21) 29 (17)
Exon 21 point mutation 48 (20) 11 (14) 37 (22)
Others 7 (3) 3 (4) 4 (2)
WT or uninvestigated 146 (59) 46 (61) 100 (59)
Inflammatory lung disease
Present 22 (9) 10 (13) 12 (7) 0.147
Absent 224 (91) 66 (87) 158 (93)
Serum CEA
Positive 163 (66) 53 (70) 110 (65) 0.469
Negative 83 (34) 23 (30) 60 (35)
Serum CYFRA 21-1
Positive 155 (63) 59 (78) 96 (56) 0.002
Negative 91 (37) 17 (22) 74 (44)
Chemotherapy
Platinum doublet 170 (69) 43 (57) 127 (75) 0.007
Others 76 (31) 33 (43) 43 (25)
CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CYFRA 21-1 cytokeratin 19 fragments, ECOG PS Eastern Cooperative Oncology Group
Performance Status, EGFR epidermal growth factor receptor gene, SD standard deviation, WT wild-type
*Comparison between patients with mutated EGFR and those with WT or uninvestigated EGFR
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(n = 170, 69 %) was 12.5 months (95 % CI [CI]: 9.7 −
16.9 months); that of serum CA 19-9− patients (n = 76,
31 %) was 26.2 months (CI: 21.8 − 28.8 months; P < 0.001).
The OS of serum CYFRA 21-1+ patients (n = 155, 63 %)
was 16.9 months (CI: 12.6 − 19.7 months), and that of
serum CYFRA 21-1− patients (n = 91, 37 %) was
31.8 months (CI: 26.2 − 43.9 months; P < 0.001).
Multivariate analysis of overall survival time
Cox’s multivariate regression analysis of the influence of
clinical characteristics on survival outcomes indicated
that ECOG PS 0 or 1 (HR: 0.42, CI: 0.29 − 0.62, P < 0.001),
mutated EGFR status (HR: 0.41, CI: 0.29 − 0.57, P < 0.001),
stage IIIB (HR: 0.38, CI: 0.21 − 0.64, P < 0.001), serum
CYFRA 21-1− (HR: 0.47, CI: 0.32 − 0.66, P < 0.001), serum
CA 19-9− (HR: 0.60, CI: 0.43 − 0.85, P = 0.005), and ad-
ministration of platinum doublet therapy (HR: 0.64, CI:
0.42 − 0.97, P = 0.034) independently predicted longer OS.
To clarify the relationships of chemotherapy regimens to
OS, we analyzed the platinum doublet subcohorts with re-
gard to OS; we found that CA 19-9− independently pre-
dicted longer OS (HR: 0.54, CI:0.35 − 0.84, P = 0.007).
OS by combined serum levels of CA 19-9 and CYFRA 21-1
We initially divided the patients into 4 groups by serum
CA 19-9 and CYFRA 21-1 level: (a) both CA 19-9+ and





Univariate analysis Multivariate analysis
P HR (95 % CI) P
Age (years)
≥ 75 62 (25) 15.1 0.005 1.35 (0.90–1.99) 0.150
< 75 184 (75) 24.2 Reference
Sex
Male 154 (63) 19.1 0.279 1.30 (0.87–1.97) 0.204
Female 92 (37) 26.2 Reference
Smoking status
Never 101 (41) 23.8 0.742 0.91 (0.64–1.36) 0.636
Current or former 145 (59) 19.3 Reference
ECOG PS
0 or 1 184 (75) 26.5 <0.001 0.42 (0.29–0.62) <0.001
2–4 62 (25) 8.8 Reference
EGFR status
Mutated 100 (41) 31.1 0.001 0.41 (0.29–0.57) <0.001
WT or uninvestigated 146 (59) 16.9 Reference
Stage
IIIB 26 (11) 43.9 0.016 0.38 (0.21–0.64) <0.001
IV 220 (89) 20.2 Reference
Serum CEA
Negative 83 (34) 20.4 0.985 0.79 (0.56–1.11) 0.180
Positive 163 (66) 21.8 Reference
Serum CYFRA 21-1
Negative 91 (37) 31.8 <0.001 0.47 (0.32–0.66) <0.001
Positive 155 (63) 16.9 Reference
Serum CA 19-9
Negative 170 (69) 26.2 <0.001 0.60 (0.43–0.85) 0.005
Positive 76 (31) 12.5 Reference
Chemotherapy
Platinum doublet 170 (69) 25.0 <0.001 0.64 (0.42–0.97) 0.034
Others 76 (31) 14.2 Reference
CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CI confidence interval, CYFRA 21-1 cytokeratin 19 fragments, ECOG PS Eastern Cooperative
Oncology Group Performance Status, EGFR epidermal growth factor receptor gene, WT wild-type, HR hazard ratio, OS overall survival
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CYFRA 21-1+ (59 patients, 24 %; median survival time
[MST]: 10.0 months [CI: 8.8 − 13.4 months]), (b) CA 19-9+
and CYFRA 21-1− (17 patients, 7 %; MST: 26.7 months [CI:
12.5 − * months]), (c) CA 19-9− and CYFRA 21-1+ (96 pa-
tients, 39 %; MST: 22.5 months [CI: 16.9 − 26.6 months]),
and (d) both CA 19-9− and CYFRA 21-1− (74 patients,
30 %; MST: 31.8 months [CI: 25.0 − 58.5 months]). Al-
though the MSTs of (a) and (b) (P = 0.001) and that of (c)
and (d) (P = 0.003) differed statistically, the difference be-
tween the two single-positive groups, (b) and (c), was not
significant (P = 0.14). Therefore, we combined groups (b)
and (c) into one single positive group. We also defined
group (a) as double positive and group (d) as double
negative (Fig. 2). Survival curves for these 3 groups are
shown in Fig. 3b. Their MSTs were double positive:
10.0 months (CI: 8.8 − 13.4 months); single positive:
23.2 months (CI: 19.3 − 26.7 months); and double nega-
tive: 31.8 months (CI: 25.0 − 58.5 months; P < 0.001).
Pathological findings and recurrence-free survival analysis
We pathologically evaluated 116 consecutive surgically
resected specimens from patients with clinical stage I
lung adenocarcinoma. Of those, 54 (47 %) were CA
19-9+. Relationships between CA 19-9 expression and
patients’ clinicopathological characteristics are sum-
marized in Table 3. Comparison of clinical profiles of
CA 19-9+ and CA 19-9− patients showed the CA 19-9+
group to include significantly higher proportions of pa-
tients with vessel invasion (P = 0.032), pleural invasion
(P = 0.023), cancer invasive factors (P = 0.005) and
positive PAS stain (P = 0.001). CA 19-9+ patients had
significantly shorter recurrence-free survival than CA
19-9− patients (P = 0.030). The Kaplan-Meier curve is
shown in Fig. 4. We also investigated the association
between EGFR status and survival in the 116 patients
with stage I lung adenocarcinoma; for whom 110
(95 %) had EGFR mutation analyses available, which
showed 61 (53 %) to have EGFR mutations. Log-lank
analysis revealed that EGFR status had no prognostic
effect on recurrence-free survival (P = 0.569), or OS
(P = 0.171).
Discussion
In the present study, we showed that both serum CA
19-9 and CYFRA 21-1 were independent prognostic
markers in ALAD patients, and their combined use im-
proves prognostic accuracy.
We have shown serum CA 19-9 to be an independent
predictive factor for OS, according to multivariate ana-
lysis of possible prognostic factors that included serum
CYFRA 21-1. To the best of our knowledge, this is the
first report to show the correlation between positive CA
19-9 levels and shorter OS in patients with ALAD, al-
though this correlation has been reported in adenocar-
cinomas of other organs such as pancreas, colon, and
stomach [8–15]. The consistency of this pattern among
adenocarcinomas of different organs implies that serum
CA 19-9 might be a prognostic marker in all kinds of
adenocarcinoma.
The major advantage of CA 19-9 is that it can be mea-
sured quickly at low cost. Additionally, CA 19-9 is a
standard biomarker for gastrointestinal cancers, such as
pancreatic, colon, and gastric cancers. Therefore we
speculate that its application to lung cancer would be
relatively easy.
Our results also showed that 31 % of ALAD patients
had positive serum CA 19-9. We believe that this posi-
tive rate is common in patients with ALAD, although it
was much lower than in studies of patients with advanced
pancreatic adenocarcinoma (for which CA 19-9 is a prog-
nostic marker), who were reportedly 50 % − 84 % positive
[8, 10, 30].
The combined use of CA 19-9 and CYFRA 21-1 offers
more accurate prognoses in patients with lung adenocar-
cinoma. In our study, as patients who were either CA
19-9+ or CYFRA 21-1+ did not significantly differ in
Fig. 3 Kaplan–Meier curves for overall survival in patients with advanced stage disease, by (a) serum CA 19-9 positivity; and (b) both serum CA
19-9 and serum CYFRA 21-1 (Double −: neither marker; Single +: one marker; Double +: both markers)
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survival, we regarded them as one group (single positive
patients). Consequently, we divided patients into three
groups as well; 24 % double positive (CA 19-9+/CYFRA
21-1+), 46 % single positive (either CA 19-9+ or CYFRA
21-1+), and 30 % double negative (CA 19-9−/CYFRA
21-1−). Survival curves for these 3 groups revealed signifi-
cant relationships between these tumor markers and
prognosis (Fig. 3b).
The precise reason for high CA 19-9 levels is unclear.
However, large studies have shown that healthy volun-
teers did not have high serum CA 19-9 levels [31, 32].
High CA 19-9 elevation has been reported in some
chronic inflammatory lung diseases, such as intestinal
pneumonia, NTM infection, bronchiectasis, and diffuse
panbronchiolitis [33]. In the present study, CA 19-9
positivity and presence of inflammatory disease showed
no correlation (P = 0.147); thus inflammatory disease did
not cause CA 19-9 elevation. In addition, our patho-
logical analysis demonstrated that the lung cancer cells
generated CA 19-9. Therefore, we speculated the ele-
vated serum CA 19-9 was associated with the CA 19-9
generated by cancer cells.
Although CA 19-9 expression is also related to un-
favorable prognosis in some kinds of cancer, why high
CA 19-9 predict shorter OS is not understood [34, 35]. We
therefore investigated the relationship between CA 19-9
IHC positivity and pathological findings in patients with
stage I lung adenocarcinoma. We analyzed the presence of
Table 3 Relationships between serum CA 19-9 and clinicopathological factors in clinical stage I lung adenocarcinoma patients
Patient characteristics CA 19-9 positive n (%) (n = 54) CA 19-9 negative n (%) (n = 62) P
Age (years)
SD 9.1 8.3 0.028
Mean 69.2 65.6
Sex
Male 29 (54) 30 (48) 0.582
Female 25 (46) 32 (52)
Smoking status
Never 30 (56) 32 (52) 0.712
Current or former 24 (44) 30 (48)
Vessel invasion
Absent 39 (72) 55 (89) 0.032
Present 15 (28) 7 (11)
Pleural invasion
Absent 41 (76) 57 (92) 0.023
Present 13 (24) 5 (8)
p-N status
No metastasis 47 (87) 59 (95) 0.184
Metastasis 7 (13) 3 (5)
Cancer invasive factor
Negative 29 (54) 49 (79) 0.005
Positive 25 (46) 13 (21)
c-Stagea
IA 44 (81) 50 (81) 1.000
IB 10 (19) 12 (19)
p-Stageb
I 45 (83) 59 (95) 0.063
II/III 9 (17) 3 (5)
PAS stain
Negative 32 (59) 54 (87) 0.001
Positive 22 (41) 8 (13)
CA 19-9 carbohydrate antigen 19-9, PAS periodic acid-Schiff stain, SD standard deviation
a Clinical stage; b Pathological stage
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cancer invasive factors (vessel and pleural invasion) and
mucin production, which were reportedly associated with
highly malignant features such as shorter recurrence-free
survival and OS in lung adenocarcinoma patients
[24, 29, 36]. In our pathological analysis of clinical stage
I patients, CA 19-9 positive lung adenocarcinoma had
more histologically malignant features (P = 0.005) and
shorter recurrence-free survival (P = 0.030) than CA 19-9
negative lung adenocarcinoma (Fig. 4). These findings
indicate that CA 19-9 positive lung adenocarcinoma is
highly malignant. We speculate that these malignant
features caused the elevated serum CA 19-9, as cancer
cell invasion to the blood could cause the elevated
serum tumor markers.
Our findings are of special interest, but there were
some limitations to this study. First, as this study was
conducted in a single institute, it included limited num-
ber of patients. Second, a considerable number of pa-
tients were excluded from this analysis due to missing
tumor marker data before their initial therapy, because
measurement of tumor markers was at the discretion of
the attending physician. Third, subject selection in this
study was confined to Japanese patients, and racial dif-
ferences may need to be considered in the interpretation
of this study. Fourth, we did not examine Lewis antigen
status [37]. Patients who are Lewis antigen-negative can-
not synthesize CA 19-9, and therefore present as falsely
negative [38]. However, as they comprise only 5–7 % of
the general population, we assume that it did not affect
the results [39].
Conclusions
In conclusion, our study showed serum CA 19-9 to be
an independent prognostic indicator in patients with
ALAD, and combined use of CA 19-9 and CYFRA 21-1
to provide more accurate prognostic information.
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